2004 Corporate Goals
- AC137 (pramlintide acetate) – Initiate Phase 2 obesity study
- AC162352 (PYY 3-36) – Initiate Phase 1 study
- Exenatide LAR – Initiate Phase 2 study
- Exenatide LAR – Report Phase 2 data
- AC137 (pramlintide acetate) for obesity – Report Phase 2 data
- AC2592 (GLP-1) – Submit IND
- AC2592 (GLP-1) – Initiate Phase 2 study